Similar to breast cancer, studies have shown promising results in treating salivary gland cancers with a high HER2/neu overexpression, such as SDC and CXPA, with targeted therapy having HER2/neu as a molecular target [33–36]. This evidence concerns the gene ERBB2 and breast carcinoma.